Key result
Continuous intravenous infusion of oxycodone successfully relieved refractory dyspnea in a patient with end-stage heart failure and severe renal dysfunction.
Why the study?
Does continuous intravenous infusion of oxycodone improve dyspnea in a patient with end-stage heart failure and severe renal dysfunction?
Case Report (n=1)
No
Does continuous intravenous infusion of oxycodone improve dyspnea in a patient with end-stage heart failure and severe renal dysfunction?
Continuous intravenous infusion of oxycodone may safely alleviate dyspnea in end-stage heart failure patients with severe renal dysfunction who cannot tolerate morphine.
May offer dyspnea relief option when morphine contraindicated in end-stage HF; hypothesis-generating case report requiring controlled trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ishii et al. (2016) conducted a case report in End-stage heart failure due to dilated cardiomyopathy with dyspnea (n=1). Continuous intravenous infusion of oxycodone was evaluated on Relief of dyspnea (modified Borg Scale). Continuous intravenous infusion of oxycodone successfully relieved refractory dyspnea in a patient with end-stage heart failure and severe renal dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: